SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotransplant(BTRN) -- Ignore unavailable to you. Want to Upgrade?

To: Arthur Radley who wrote (1268)3/5/2002 9:40:26 AM
From: scaram(o)uche  Read Replies (2) | Respond to of 1475
 
>> why bother with this trial <<

There are still organs that are lost to acute (not hyperacute, not mediated by antibody) rejection. I'm all for using an adjunct, early in the allotransplant process. Could be a big plus. But they wrote the release to imply that it could be more, IMO.

I feel that this company is rather leaning a tad toward deceptive, and believe that they should clean up their reporting.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News